Verrica Pharmaceuticals (VRCA) Non-Current Assets (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Non-Current Assets of $4.7 million for Q1 2026, up 72.23% year-over-year from $2.7 million in Q1 2025, and up 1.42% quarter-over-quarter from $4.6 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Non-Current Assets (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Non-Current Assets history runs 9 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 72.23% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $16.2 million (up 7.32% YoY), while the FY2025 annual figure was $4.6 million, up 55.4% from the prior year.
- Non-Current Assets for Q1 2026 stood at $4.7 million, up from $4.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $6.1 million in Q2 2022, with the low at $2.3 million in Q2 2025.
- The 5-year median for Non-Current Assets is $4.7 million (2024), against an average of $4.7 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 50.43% in 2025, then jumped 72.23% in 2026.
- Verrica Pharmaceuticals' Non-Current Assets stood at $5.6 million in 2022, then dropped by 27.45% to $4.1 million in 2023, then decreased by 27.34% to $3.0 million in 2024, then surged by 55.4% to $4.6 million in 2025, then increased by 1.42% to $4.7 million in 2026.
- Business Quant data shows VRCA's Non-Current Assets at $4.7 million in Q1 2026, $4.6 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Mn |
| Mar 31, 2026 | 4.66 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 4.69 Mn |
| Mar 31, 2024 | 4.93 Mn |
| Dec 31, 2023 | 4.07 Mn |
| Sep 30, 2023 | 5.42 Mn |
| Jun 30, 2023 | 5.42 Mn |
| Mar 31, 2023 | 5.54 Mn |
| Dec 31, 2022 | 5.61 Mn |
| Sep 30, 2022 | 5.75 Mn |
| Jun 30, 2022 | 6.10 Mn |
| Mar 31, 2022 | 5.85 Mn |
| Dec 31, 2021 | 5.80 Mn |
| Sep 30, 2021 | 5.60 Mn |